Baird Downgrades Medpace(MEDP.US) to Hold Rating, Cuts Target Price to $349

貝雅下調Medpace(MEDP.US)至持有評級，下調目標價至349美元

moomoo資訊 · 10/23 05:31 · 評級/大行評級

Baird analyst Eric Coldwell downgrades $Medpace (MEDP.US)$ to a hold rating, and adjusts the target price from $413 to $349.

According to TipRanks data, the analyst has a success rate of 53.2% and a total average return of 4.5% over the past year.

AnalystRecentRatingAutoNews_212031_20241023_1ea97f462c1c475d553a68738d9cc43bedb3fc94_1729765844267730_mm_en

Furthermore, according to the comprehensive report, the opinions of $Medpace (MEDP.US)$'s main analysts recently are as follows:

The company anticipates that cancellations from the first through the third quarter will continue, potentially impacting the book-to-bill from the fourth quarter of 2024 to the second quarter of 2025. This situation might make a return to a 1.2x book-to-bill ratio unlikely until the second half of 2025 at the earliest.
It is anticipated that Medpace may not experience significant multiple expansion due to the low net new business, with a potential decline in revenue growth by 2025. Nonetheless, the company's current cancellation issues are expected to be temporary and could lead to a robust reacceleration in 2026.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

貝雅分析師Eric Coldwell下調$Medpace (MEDP.US)$至持有評級，並將目標價從413美元下調至349美元。

根據TipRanks數據顯示，該分析師近一年總勝率為53.2%，總平均回報率為4.5%。

AnalystRecentRatingAutoNews_212031_20241023_1ea97f462c1c475d553a68738d9cc43bedb3fc94_1729765844267730_mm_tc

此外，綜合報道，$Medpace (MEDP.US)$近期主要分析師觀點如下：

該公司預計，從第一季度到第三季度的取消將持續下去，這可能會影響2024年第四季度至2025年第二季度的賬面賬單比率。因此，預計最早要到2025年下半年才能恢復到1.2倍的賬面賬單比率。
預計由於淨新業務較低，Medpace可能不會進行重大的多次擴張，到2025年，收入增長可能會下降。儘管如此，該公司目前的取消問題預計將是暫時的，並可能導致2026年強勁復甦。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Baird Downgrades Medpace(MEDP.US) to Hold Rating, Cuts Target Price to $349

Baird Downgrades Medpace(MEDP.US) to Hold Rating, Cuts Target Price to $349

風險及免責聲明

聲明